Daratumumab for the treatment of AL amyloidosis

M. Hasib Sidiqi, Morie A. Gertz

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Autologous stem cell transplantation (ASCT) has been used as treatment for immunoglobulin light-chain (AL) amyloidosis for over two decades with improving outcomes; however, the majority of patients are not candidates for this therapy at diagnosis. Novel agents such as immunomodulatory drugs, proteasome inhibitors, and immunotherapy with monoclonal antibodies targeting CD38 have been adopted from the multiple myeloma spheres with encouraging results. Herein, we discuss the role of daratumumab, a monoclonal antibody to CD38, in the treatment of AL amyloidosis. We focus on its mechanism of action, tolerability, and the current published data on its use in AL amyloidosis. Early data from phase I and phase II studies show that daratumumab is tolerated well in this population and induces rapid and deep responses. Phase III trials are currently accruing and we envision daratumumab becoming a key component in the treatment of AL amyloidosis in the future.

Original languageEnglish (US)
Pages (from-to)295-301
Number of pages7
JournalLeukemia and Lymphoma
Issue number2
StatePublished - Jan 28 2019


  • AL amyloidosis
  • CD38
  • Daratumumab
  • immunotherapy
  • monoclonal antibody

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Daratumumab for the treatment of AL amyloidosis'. Together they form a unique fingerprint.

Cite this